company background image
2142 logo

HBM Holdings SEHK:2142 Stock Report

Last Price

HK$1.09

Market Cap

HK$798.6m

7D

-12.1%

1Y

-49.3%

Updated

17 Apr, 2024

Data

Company Financials

2142 Stock Overview

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas.

2142 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 2142 from our risk checks.

HBM Holdings Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HBM Holdings
Historical stock prices
Current Share PriceHK$1.09
52 Week HighHK$2.21
52 Week LowHK$1.06
Beta1.47
1 Month Change-26.85%
3 Month Change-31.45%
1 Year Change-49.30%
3 Year Change-88.60%
5 Year Changen/a
Change since IPO-90.11%

Recent News & Updates

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12
Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Recent updates

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12
Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01
HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08
We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

May 30
HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Apr 07
Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Mar 31
Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Mar 10
What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Shareholder Returns

2142HK BiotechsHK Market
7D-12.1%-7.6%-1.9%
1Y-49.3%-47.1%-16.4%

Return vs Industry: 2142 underperformed the Hong Kong Biotechs industry which returned -47.1% over the past year.

Return vs Market: 2142 underperformed the Hong Kong Market which returned -16.4% over the past year.

Price Volatility

Is 2142's price volatile compared to industry and market?
2142 volatility
2142 Average Weekly Movement8.1%
Biotechs Industry Average Movement9.5%
Market Average Movement7.4%
10% most volatile stocks in HK Market14.8%
10% least volatile stocks in HK Market3.8%

Stable Share Price: 2142's share price has been volatile over the past 3 months.

Volatility Over Time: 2142's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016177Jingsong Wangwww.harbourbiomed.com

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9378 for the treatment of Asthma; and HBM1020, HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors.

HBM Holdings Limited Fundamentals Summary

How do HBM Holdings's earnings and revenue compare to its market cap?
2142 fundamental statistics
Market capHK$798.55m
Earnings (TTM)HK$178.52m
Revenue (TTM)HK$700.86m

4.5x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2142 income statement (TTM)
RevenueUS$89.50m
Cost of RevenueUS$2.03m
Gross ProfitUS$87.47m
Other ExpensesUS$64.67m
EarningsUS$22.80m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.031
Gross Margin97.73%
Net Profit Margin25.47%
Debt/Equity Ratio53.8%

How did 2142 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.